Digital Pathology and AI Assisted Microscopy Market - Forecasts from 2026 to 2031

The Digital Pathology and AI Assisted Microscopy market is projected to grow from an estimated USD 1.6 billion in 2026 to USD 3.7 billion by 2031. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 18.3% over the forecast period.

The market encompasses several critical components, including imaging systems, digital slide scanners, AI analysis software, and data management platforms. These technologies are instrumental in converting traditional analogue histopathology to efficient digital workflows, enabling rapid image sharing and quantitative analysis.

The escalating demand is primarily driven by the increasing incidence and prevalence of major diseases, such as ~20 million new cancer cases globally each year. These solutions are crucial for efficient diagnostics, decreasing turnaround times, enhancing accuracy in diagnosing disease states like cancer and infections, and facilitating remote collaboration.

Regulatory authorities such as the U.S. FDA and the European Union MDR are actively creating frameworks for AI's integration, focusing on safety and effectiveness. Furthermore, countries like the UK are developing national platforms, such as the National Pathology Imaging Cooperative, to deploy digital pathology networks and AI analytical processes at scale across the country.

AI is increasingly integrated into digital pathology workflows to significantly aid in the detection, quantification, and complex analysis of tumours. This integration not only decreases the manual labour required for such tasks but also demonstrably increases the sensitivity and specificity of diagnostic results.

The market is characterized by continued growth in innovation and collaboration among industry players, with global conferences showcasing cutting-edge AI technology solutions. Examples include automated assessments of tumour cellularity and the integration of AI use (AuP) approaches, highlighting a dynamic environment focused on advanced diagnostic capabilities.